Literature DB >> 3243433

Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).

M Matsukura1, G Zon, K Shinozuka, C A Stein, H Mitsuya, J S Cohen, S Broder.   

Abstract

Nuclease-resistant phosphorothioate analogues of oligodeoxynucleotides (oligos) were synthesized by sulfurization of either internucleoside phosphite linkages, in a repetitive manner during chain extension, or internucleoside hydrogen phosphonate linkages, in a single step following chain assembly. These analogues were tested as antiviral agents against human immunodeficiency virus (HIV). In a cytopathic effect inhibition assay using HIV-uninfected susceptible T cells (tetanus toxoid-specific normal T cells) co-cultured with irradiated chronically HIV-infected cells, phosphorothioate oligomers inhibited the cytopathic effect and replication of several isolates of HIV-1 and HIV-2. Thus phosphorothioate analogues of oligos could inhibit cell-to-cell transmission of the virus as well as the infection by cell-free virus particles and also could inhibit a variety of isolates of human retroviruses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243433     DOI: 10.1016/0378-1119(88)90161-8

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  15 in total

1.  Synthesis of well-defined phosphate-methylated DNA fragments: the application of potassium carbonate in methanol as deprotecting reagent.

Authors:  W H Kuijpers; J Huskens; L H Koole; C A van Boeckel
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

Review 2.  Antisense approaches to the gene therapy of cancer--'Recnac'.

Authors:  I Gibson
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 3.  Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.

Authors:  G Zon
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

4.  Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

Authors:  G Li; J Lisziewicz; D Sun; G Zon; S Daefler; F Wong-Staal; R C Gallo; M E Klotman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers.

Authors:  L Kibler-Herzog; G Zon; B Uznanski; G Whittier; W D Wilson
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

7.  Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents.

Authors:  R P Iyer; B Uznanski; J Boal; C Storm; W Egan; M Matsukura; S Broder; G Zon; A Wilk; M Koziolkiewicz
Journal:  Nucleic Acids Res       Date:  1990-05-25       Impact factor: 16.971

8.  Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity.

Authors:  J Y Tang; J Temsamani; S Agrawal
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

9.  Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.

Authors:  J Lisziewicz; D Sun; M Klotman; S Agrawal; P Zamecnik; R Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses.

Authors:  D Archambault; C A Stein; J S Cohen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.